Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric Clinical-Practice Based Cohort Study Evaluating Effectiveness And Identifying Predictors Of Response To Belimumab In Patients With Active Systemic lupus erythematosus (SLE)

Trial Profile

A Multicentric Clinical-Practice Based Cohort Study Evaluating Effectiveness And Identifying Predictors Of Response To Belimumab In Patients With Active Systemic lupus erythematosus (SLE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2018 Results assessing safety and efficacy of response to belimumab in patients with active Systemic Lupus Erythematosus, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 17 Jun 2017 Results (n=48) assessing the effect of belimumab treatment on skin involvement, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top